Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Gilead Sciences

Related GILD
Early Global News: Ebola In Liberia, Boeing To Roll Out 737 MAX Next Month, Google Testing SMS Alerts
Gilead's Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Strong Drug Development Benefits Cambrex (Investor's Business Daily)

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD), but lowered its price target from $95.00 to $48.00.

Deutsche Bank noted, “We are updating our TP and EPS estimates for Gilead's recent 2:1 stock split. Our new TP is $48 & our pre-split TP was $95. Our new 4Q12, FY 2012 and 2013 non-GAAP EPS estimates are $.51, $1.98, and $2.35 respectively. New 4Q12 fully diluted share count is 1582 with average share count of 1568 for FY 2012. We have made no changes to our revenue projections or expenses. Our thesis remains unchanged on HCV & HIV.”

Gilead Sciences closed on Tuesday at $39.90.

Latest Ratings for GILD

Nov 2015Piper JaffrayUpgradesNeutralOverweight
Oct 2015OppenheimerMaintainsOutperform
Oct 2015JefferiesMaintainsHold

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters